Journal article
Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo
LM Judd, TR Menheniott, H Ling, CB Jackson, M Howlett, A Kalantzis, W Priebe, AS Giraud
Plos One | Published : 2014
Abstract
Signal Transducer and Activator of Transcription-3 (STAT3) is constitutively activated in many cancers where it promotes growth, inflammation, angiogenesis and inhibits apoptosis. We have shown that STAT3 is constitutively activated in human gastric cancer, and that chronic IL-11-driven STAT3 transcriptional activity induces gastric tumourigenesis in the gp130 757FF mouse model of gastric cancer development. Here we show that treatment of human AGS gastric cancer cells with the Janus Kinase (JAK) inhibitor WP1066 dose-, and time-dependently inhibits STAT3 phosphorylation, in conjunction with reduced JAK2 phosphorylation, reduced proliferation and increased apoptosis. In addition, application..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This project was supported by funds from; NHMRC Australia (www.nhmrc.gov.au) project grant # 509165 NIH/NCI USA (nih.gov; www. cancer. gov) melanoma SPORE P50 CA093459-06, NIH/NCI USA (nih. gov; www. cancer. gov) brain SPORE 2 P50 CA127001-06. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.